Dasatinib-Induced Chylothorax in Chronic Myeloid Leukemia
Internal Medicine (East Africa)
Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib treatment.
Baylor University Medical Center Proceedings
Baloch, Z. Q.,
Shabber, A. A.,
(2017). Dasatinib-Induced Chylothorax in Chronic Myeloid Leukemia. Baylor University Medical Center Proceedings, 30(1), 71-73.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med/305